There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report) and Polynovo Limited (CALZF – Research Report) with bullish sentiments.
Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $21.00. The company’s shares closed last Wednesday at $7.65, close to its 52-week low of $6.91.
According to TipRanks.com, Wolleben has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.75.
See today’s best-performing stocks on TipRanks >>
Polynovo Limited (CALZF)
Bell Potter analyst John Hester maintained a Buy rating on Polynovo Limited on December 2 and set a price target of A$2.30. The company’s shares closed last Monday at $1.40, close to its 52-week high of $1.50.
According to TipRanks.com, Hester is a 4-star analyst with an average return of
Currently, the analyst consensus on Polynovo Limited is a Moderate Buy with an average price target of $1.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTGX: